Ignite Creation Date:
2025-12-24 @ 3:07 PM
Ignite Modification Date:
2025-12-28 @ 11:18 AM
Study NCT ID:
NCT05156892
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-05-15
First Post:
2021-10-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
Sponsor:
Anthony Joshua, FRACP
Organization:
Study Overview
Official Title:
A Phase I/II Trial Investigating the Tolerability, Toxicity and Efficacy of Tamoxifen and SUBA-Itraconazole in Patients With Platinum Resistant Recurrent Epithelial Ovarian Cancer
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2025-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TICTOC
Brief Summary:
The study's purpose is to understand the effects of a new treatment (suba-itraconazole and tamoxifen) in epithelial ovarian cancer.
Who is it for? Patients may be eligible to join this study with ovarian cancer resistant to platinum-based chemotherapy agents
Study Details:
Participants will receive different doses of tamoxifen and suba-itraconazole to determine the optimal combination dose.
Participants will be seen by the investigators once a week for the first 3 weeks and then once every 4 weeks. Participant will be reviewed by a clinician and undergo regular blood tests, cardiac monitoring and imaging assessments.
Who is it for? Patients may be eligible to join this study with ovarian cancer resistant to platinum-based chemotherapy agents
Study Details:
Participants will receive different doses of tamoxifen and suba-itraconazole to determine the optimal combination dose.
Participants will be seen by the investigators once a week for the first 3 weeks and then once every 4 weeks. Participant will be reviewed by a clinician and undergo regular blood tests, cardiac monitoring and imaging assessments.
Detailed Description:
A phase 1/2 study of Suba-itraconazole and Tamoxifen in platinum resistant ovarian carcinoma
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: